Controversies in primary treatment of low-risk papillary thyroid cancer

Sherman, 2003, Thyroid carcinoma, Lancet, 361, 501, 10.1016/S0140-6736(03)12488-9 Cooper, 2009, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 19, 1167, 10.1089/thy.2009.0110 Tuttle, 2012 Pitoia, 2009, Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer, Arq Bras Endocrinol Metabol, 53, 884, 10.1590/S0004-27302009000700014 Pacini, 2006, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur J Endocrinol, 154, 787, 10.1530/eje.1.02158 2007 Takami, 2011, Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons, World J Surg, 35, 111, 10.1007/s00268-010-0832-6 Sisson, 2011, Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association, Thyroid, 21, 335, 10.1089/thy.2010.0403 Xing, 2013, Progress in molecular-based management of differentiated thyroid cancer, Lancet, 381, 1058, 10.1016/S0140-6736(13)60109-9 Ferlay Howlader Davies, 2006, Increasing incidence of thyroid cancer in the United States, 1973–2002, JAMA, 295, 2164, 10.1001/jama.295.18.2164 Hall, 2009, Increasing detection and increasing incidence in thyroid cancer, World J Surg, 33, 2567, 10.1007/s00268-009-0226-9 Grodski, 2008, Increasing incidence of thyroid cancer is due to increased pathologic detection, Surgery, 144, 1038, 10.1016/j.surg.2008.08.023 Davies, 2010, The increasing incidence of small thyroid cancers: where are the cases coming from?, Laryngoscope, 120, 2446, 10.1002/lary.21076 Liu, 2001, Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects, Br J Cancer, 85, 1335, 10.1054/bjoc.2001.2061 Montanaro, 2006, Unexpected additional increase in the incidence of thyroid cancer among a recent birth cohort in Switzerland, Eur J Cancer Prev, 15, 178, 10.1097/01.cej.0000197450.94980.36 Colonna, 2007, A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000), Eur J Cancer, 43, 891, 10.1016/j.ejca.2006.11.024 Dal Maso, 2011, Incidence of thyroid cancer in Italy, 1991–2005: time trends and age-period-cohort effects, Ann Oncol, 22, 957, 10.1093/annonc/mdq467 Blomberg, 2012, Thyroid cancer in Denmark 1943–2008, before and after iodine supplementation, Int J Cancer, 131, 2360, 10.1002/ijc.27497 Chen, 2009, Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005, Cancer, 115, 3801, 10.1002/cncr.24416 Enewold, 2011, Thyroid cancer incidence among active duty US military personnel, 1990–2004, Cancer Epidemiol Biomarkers Prev, 20, 2369, 10.1158/1055-9965.EPI-11-0596 Morris, 2010, Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis, Am J Surg, 200, 454, 10.1016/j.amjsurg.2009.11.008 Gomez Segovia, 2004, Thyroid, 14, 277, 10.1089/105072504323030933 Kazaure, 2012, Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients, Ann Surg Oncol, 19, 1874, 10.1245/s10434-011-2129-x 2010, Thyroid, 87 Hay, 1993, Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989, Surgery, 114, 1050 Cady, 1988, An expanded view of risk-group definition in differentiated thyroid carcinoma, Surgery, 104, 947 Lang, 2007, Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers, Ann Surg, 246, 114, 10.1097/01.sla.0000262785.46403.9b Tanaka, 2012, Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan: results of a questionnaire distributed to councilors of the Japanese Society of thyroid surgery, Surg Today, 42, 633, 10.1007/s00595-011-0091-7 Tuttle, 2010, Thyroid, 20, 1341, 10.1089/thy.2010.0178 Udelsman, 2005, Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer?, Lancet Oncol, 6, 529, 10.1016/S1470-2045(05)70247-3 Udelsman, 1996, Optimal surgery for papillary thyroid carcinoma, World J Surg, 20, 88, 10.1007/s002689900016 Katoh, 1992, Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma: a clinicopathologic study of 105 consecutive patients, Cancer, 70, 1585, 10.1002/1097-0142(19920915)70:6<1585::AID-CNCR2820700623>3.0.CO;2-Z Cady, 1997, Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer, Am J Surg, 174, 462, 10.1016/S0002-9610(97)00162-1 Shaha, 2006, Treatment of thyroid cancer based on risk groups, J Surg Oncol, 94, 683, 10.1002/jso.20697 Sosa, 1998, The importance of surgeon experience for clinical and economic outcomes from thyroidectomy, Ann Surg, 228, 320, 10.1097/00000658-199809000-00005 Shaha, 1997, Low-risk differentiated thyroid cancer: the need for selective treatment, Ann Surg Oncol, 4, 328, 10.1007/BF02303583 Hay, 1998, Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?, Surgery, 124, 958, 10.1016/S0039-6060(98)70035-2 Cross, 2006, Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer, J Surg Oncol, 94, 678, 10.1002/jso.20698 DeGroot, 1990, Natural history, treatment, and course of papillary thyroid carcinoma, J Clin Endocrinol Metab, 71, 414, 10.1210/jcem-71-2-414 Samaan, 1992, The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients, J Clin Endocrinol Metab, 75, 714 Nixon, 2012, Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy, Surgery, 151, 571, 10.1016/j.surg.2011.08.016 Baudin, 1998, Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience, Cancer, 83, 553, 10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO;2-U Ross, 2009, Recurrence after treatment of micropapillary thyroid cancer, Thyroid, 19, 1043, 10.1089/thy.2008.0407 Hay, 2008, Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period, Surgery, 144, 980, 10.1016/j.surg.2008.08.035 Bilimoria, 2007, Extent of surgery affects survival for papillary thyroid cancer, Ann Surg, 246, 375, 10.1097/SLA.0b013e31814697d9 Haigh, 2005, Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer, Ann Surg Oncol, 12, 81, 10.1007/s10434-004-1165-1 Mendelsohn, 2010, Surgery for papillary thyroid carcinoma: is lobectomy enough?, Arch Otolaryngol Head Neck Surg, 136, 1055, 10.1001/archoto.2010.181 Barney, 2011, Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer, Head Neck, 33, 645, 10.1002/hed.21504 Esnaola, 2001, Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis, Surgery, 130, 921, 10.1067/msy.2001.118370 Kebebew, 2000, Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model, World J Surg, 24, 1295, 10.1007/s002680010215 Shrime, 2007, Cost-effective management of low-risk papillary thyroid carcinoma, Arch Otolaryngol Head Neck Surg, 133, 1245, 10.1001/archotol.133.12.1245 Carty, 2009, Consensus statement on the terminology and classification of central neck dissection for thyroid cancer, Thyroid, 19, 1153, 10.1089/thy.2009.0159 Attie, 1988, Modified neck dissection in treatment of thyroid cancer: a safe procedure, Eur J Cancer Clin Oncol, 24, 315, 10.1016/0277-5379(88)90274-X Bardet, 2008, Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma, Eur J Endocrinol, 158, 551, 10.1530/EJE-07-0603 Ito, 2011, Significance of prophylactic modified radical neck dissection for patients with low-risk papillary thyroid carcinoma measuring 1.1–3.0 cm: first report of a trial at Kuma Hospital, Surg Today, 41, 1486, 10.1007/s00595-010-4494-7 Moreno, 2012, In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival, Thyroid, 22, 347, 10.1089/thy.2011.0121 Randolph, 2012, The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension, Thyroid, 22, 1144, 10.1089/thy.2012.0043 Chisholm, 2009, Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone, Laryngoscope, 119, 1135, 10.1002/lary.20236 Shan, 2012, Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis, Laryngoscope, 122, 797, 10.1002/lary.22162 Carling, 2012, American thyroid association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma, Thyroid, 22, 237, 10.1089/thy.2011.0317 Mazzaferri, 2009, The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma, Thyroid, 19, 683, 10.1089/thy.2009.1578 Zetoune, 2010, Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis, Ann Surg Oncol, 17, 3287, 10.1245/s10434-010-1137-6 Perrino, 2009, Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or = 2 cm, Endocr Relat Cancer, 16, 201, 10.1677/ERC-08-0119 Popadich, 2011, A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer, Surgery, 150, 1048, 10.1016/j.surg.2011.09.003 Bonnet, 2009, Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment, J Clin Endocrinol Metab, 94, 1162, 10.1210/jc.2008-1931 Hartl, 2012, Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma, Ann Surg, 255, 777, 10.1097/SLA.0b013e31824b7b68 Hughes, 2010, Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer, Surgery, 148, 1100, 10.1016/j.surg.2010.09.019 Giordano, 2012, Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature, Thyroid, 22, 911, 10.1089/thy.2012.0011 Sawka, 2008, An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer, Endocrinol Metab Clin North Am, 37, 457, 10.1016/j.ecl.2008.02.007 Eustatia-Rutten, 2004, Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis, Clin Endocrinol (Oxf), 61, 61, 10.1111/j.1365-2265.2004.02060.x Castagna, 2011, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, Eur J Endocrinol, 165, 441, 10.1530/EJE-11-0466 Vaisman, 2011, In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response, Thyroid, 21, 1317, 10.1089/thy.2011.0232 Sciuto, 2009, Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution, Ann Oncol, 20, 1728, 10.1093/annonc/mdp050 Hay, 2002, Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000, Trans Am Clin Climatol Assoc, 113, 241 Jonklaas, 2006, Outcomes of patients with differentiated thyroid carcinoma following initial therapy, Thyroid, 16, 1229, 10.1089/thy.2006.16.1229 Schvartz, 2012, Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients, J Clin Endocrinol Metab, 97, 1526, 10.1210/jc.2011-2512 Sacks, 2010, The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008, Thyroid, 20, 1235, 10.1089/thy.2009.0455 Durante, 2012, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?, J Clin Endocrinol Metab, 97, 2748, 10.1210/jc.2012-1123 Vaisman, 2010, Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma, Head Neck, 32, 689 Rosário, 2012, Postoperative stimulated thyroglobulin ≤ 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioiodine ablation, Thyroid Haymart, 2011, Use of radioactive iodine for thyroid cancer, JAMA, 306, 721, 10.1001/jama.2011.1139 Mallick, 2012, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer, N Engl J Med, 366, 1674, 10.1056/NEJMoa1109589 Schlumberger, 2012, Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med, 366, 1663, 10.1056/NEJMoa1108586 Pacini, 2006, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study, J Clin Endocrinol Metab, 91, 926, 10.1210/jc.2005-1651 Taieb, 2009, Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study, Clin Endocrinol (Oxf), 71, 115, 10.1111/j.1365-2265.2008.03424.x Wang, 2010, To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States, J Clin Endocrinol Metab, 95, 1672, 10.1210/jc.2009-1803 Van Nostrand, 2011, Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer, Oral Dis, 17, 154, 10.1111/j.1601-0825.2010.01726.x Burns, 2004, Nasolacrimal obstruction secondary to I131 therapy, Ophthal Plast Reconstr Surg, 20, 126, 10.1097/01.IOP.0000117340.41849.81 Rubino, 2003, Second primary malignancies in thyroid cancer patients, Br J Cancer, 89, 1638, 10.1038/sj.bjc.6601319 Brown, 2008, The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer, J Clin Endocrinol Metab, 93, 504, 10.1210/jc.2007-1154 Sawka, 2009, Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis, Thyroid, 19, 451, 10.1089/thy.2008.0392 Iyer, 2011, Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy, Cancer, 117, 4439, 10.1002/cncr.26070 Sawka, 2012, Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer, J Clin Oncol, 30, 2906, 10.1200/JCO.2011.41.2734 Mallick, 2012, Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo, Clin Oncol (R Coll Radiol), 24, 159, 10.1016/j.clon.2012.01.001 McLeod, 2012, Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis, J Clin Endocrinol Metab, 97, 2682, 10.1210/jc.2012-1083 Haymart, 2008, Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage, J Clin Endocrinol Metab, 93, 809, 10.1210/jc.2007-2215 McGriff, 2002, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer, Ann Med, 34, 554, 10.1080/078538902321117760 Ito, 2010, Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan, Endocr J, 57, 523, 10.1507/endocrj.K10E-019 Diessl, 2012, Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma, Clin Endocrinol (Oxf), 76, 586, 10.1111/j.1365-2265.2011.04272.x Hovens, 2007, Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer, J Clin Endocrinol Metab, 92, 2610, 10.1210/jc.2006-2566 Sugitani, 2010, Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial, J Clin Endocrinol Metab, 95, 4576, 10.1210/jc.2010-0161 Jonklaas, 2008, Triiodothyronine levels in athyreotic individuals during levothyroxine therapy, JAMA, 299, 769, 10.1001/jama.299.7.769 Mercuro, 2000, Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring, J Clin Endocrinol Metab, 85, 159, 10.1210/jcem.85.1.6298 Hoftijzer, 2008, Quality of life in cured patients with differentiated thyroid carcinoma, J Clin Endocrinol Metab, 93, 200, 10.1210/jc.2007-1203 Tan, 2007, Health-related quality of life in thyroid cancer survivors, Laryngoscope, 117, 507, 10.1097/MLG.0b013e31802e3739 Biondi, 2010, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer, Thyroid, 20, 135, 10.1089/thy.2009.0311 Biondi, 1996, Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine, J Clin Endocrinol Metab, 81, 4224 Biondi, 1993, Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine, J Clin Endocrinol Metab, 77, 334 Biondi, 1998, Clinical case seminar: reentrant atrioventricular nodal tachycardia induced by levothyroxine, J Clin Endocrinol Metab, 83, 2643, 10.1210/jcem.83.8.5000 Smit, 2005, Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study, J Clin Endocrinol Metab, 90, 6041, 10.1210/jc.2005-0620 Abdulrahman, 2011, Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma, Thyroid, 21, 471, 10.1089/thy.2010.0319 Abonowara, 2012, Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer, Clin Invest Med, 35, 152, 10.25011/cim.v35i3.16591 Bauer, 2007, Thyroid hormone use, hyperthyroidism and mortality in older women, Am J Med, 120, 343, 10.1016/j.amjmed.2006.04.034 Flynn, 2010, Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy, J Clin Endocrinol Metab, 95, 186, 10.1210/jc.2009-1625 Sugitani, 2011, Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study, Surgery, 150, 1250, 10.1016/j.surg.2011.09.013 Turner, 2011, Levothyroxine dose and risk of fractures in older adults: nested case-control study, BMJ, 342, 2238, 10.1136/bmj.d2238 Sawin, 1994, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons, N Engl J Med, 331, 1249, 10.1056/NEJM199411103311901 Bauer, 2001, Risk for fracture in women with low serum levels of thyroid-stimulating hormone, Ann Intern Med, 134, 561, 10.7326/0003-4819-134-7-200104030-00009 Kung, 1996, Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin, J Clin Endocrinol Metab, 81, 1232 Jonklaas, 2012, The impact of age and gender on papillary thyroid cancer survival, J Clin Endocrinol Metab, 97, 878, 10.1210/jc.2011-2864 Eustatia-Rutten, 2006, Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial, Clin Endocrinol (Oxf), 64, 284, 10.1111/j.1365-2265.2006.02458.x Fazio, 1995, Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade, J Clin Endocrinol Metab, 80, 2222 Panico, 2009, Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate, Thyroid, 19, 437, 10.1089/thy.2008.0428